Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

作者：Ana Oaknin, Kathleen N. Moore, Tim Meyer, José López-Picazo González, Lot A. Devriese, Asim Amin, Christopher D. Lao, Valentina Boni, William Howard Sharfman, Jong Chul Park, Makoto Tahara, Suzanne Louise Topalian, Manuel Magallanes, Alejandro Molina Alavez, Tariq Aziz Khan, Catherine Copigneaux, Michelle Lee, Charlie Garnett‐Benson, Xuya Wang, Robert Wendel Naumann · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00088-3 · 被引用次数：68 · 研究领域：Cancer Immunotherapy and Biomarkers、Endometrial and Cervical Cancer Treatments、Immunotherapy and Immune Responses